A phase 2 open-label study of lucitanib in patients (pts) with FGF aberrant metastatic breast cancer (MBC)

Authors
Category Primary study
JournalCancer Research
Year 2017
This article has no abstract
Epistemonikos ID: dc47f507e714c3243456dbf12cee8cf749a794ee
First added on: Feb 08, 2025